Cirrhosis Pipeline Review 2021

Cirrhosis is a disorder in which liver is scarred and completely damaged. Healthy liver tissue are replaced with scar tissue which prevents liver from working normally. Further, liver begins to fail, as cirrhosis gets worse. Cirrhosis has several indications, such as itchy skin and fatigue. They may not appear unless the liver is badly damaged. Causes include chronic hepatitis C, chronic hepatitis B, alcoholic liver disease, and nonalcoholic fatty liver disease. Diagnostic test involved for cirrhosis include blood tests such as liver function tests and tests for viral infections, liver biopsy, and imaging tests. The person suffering from cirrhosis should eat a healthy, well-balanced diet. The patient should avoid consumption of foods and drinks that can damage the liver, such as shellfish and alcohol.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and other components of the National Institutes of Health (NIH) support and conduct research into many diseases and conditions.

In March 2020, Zydus Cadila, an innovation-driven global pharmaceutical company, announced that the Drug Controller General of India (DCGI) has approved its New Drug Application (NDA) for Saroglitazar for the treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) in India. NASH is a progressive disease of the liver, which starts with fat accumulation in the liver known as Non-Alcoholic Fatty Liver Disease (NAFLD). This condition could progress to cirrhosis and liver failure

Approximately 60% of pipeline drugs for Cirrhosis are in phase 3 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Cirrhosis.

Report Description

The report on Cirrhosis- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Cirrhosis. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Cirrhosis (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline